# Adaptive Biotechnologies Corp (ADPT)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/adaptive-biotechnologies-corp/ JSON: https://steadybase.io/company/adaptive-biotechnologies-corp.json Checked Nov 10, 2026. Latest filing read: Nov 4, 2026.

## Company

- Legal name: Adaptive Biotechnologies Corp
- Ticker: ADPT (Nasdaq)
- SEC CIK: 0001478320
- Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
- Headquarters: Seattle, WA
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: adaptivebiotech.com
- LinkedIn: https://www.linkedin.com/company/adaptive-biotechnologies-corp-
- Next earnings date: Feb 1, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $277.0M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/0001193125-26-076902-index.html
- Operating income: -$57.1M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/0001193125-26-076902-index.html
- Net income: -$59.5M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/0001193125-26-076902-index.html
- SG&A: $167.3M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/0001193125-26-076902-index.html
- Employees: 624 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm
- Shares outstanding: 161,876,694 as of Oct 30, 2026 (10-Q filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526447411/0001193125-26-447411-index.html
- Auditor: Ernst & Young LLP, Seattle, Washington, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm

## Business

Throughout our history, we have advanced the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $277.0M | -$57.1M | -$59.5M | $167.3M |
| Dec 31, 2024 | $179.0M | -$162.5M | -$159.5M | $157.6M |
| Dec 31, 2023 | $170.3M | -$227.0M | -$225.3M | $172.5M |
| Dec 31, 2022 | $185.3M | -$200.2M | -$200.2M | $184.1M |
| Dec 31, 2021 | $154.3M | -$209.0M | -$207.3M | $170.0M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/adaptive-biotechnologies-corp.json

## Officers and directors

- Chad Robins, Chief executive officer and co-founder of Adaptive Biotechnologies. Source: 8-K filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1478320/000119312526447290/adpt-ex99_1.htm
- Chad M. Robins, CEO and Chairman. LinkedIn: https://linkedin.com/in/chad-robins-b32b933. Source: Form 4 filed Aug 19, 2026, https://www.sec.gov/Archives/edgar/data/1478320/000178064926000014/0001780649-26-000014-index.htm
- Kyle Piskel, Chief Financial Officer. LinkedIn: https://www.linkedin.com/in/kyle-piskel-18a56755. Source: Form 4 filed May 20, 2026, https://www.sec.gov/Archives/edgar/data/1478320/000178066226000013/0001780662-26-000013-index.htm
- Julie Rubinstein, President and COO. Source: Form 4 filed Apr 29, 2026, https://www.sec.gov/Archives/edgar/data/1478320/000178066426000032/0001780664-26-000032-index.htm
- Francis Lo, Chief People Officer. LinkedIn: https://linkedin.com/in/lofrancis. Source: Form 4 filed Sep 18, 2026, https://www.sec.gov/Archives/edgar/data/1478320/000178066026000022/0001780660-26-000022-index.htm
- Susan Bobulsky, Chief Commercial Officer, MRD. LinkedIn: https://linkedin.com/in/susanbobulsky. Source: Form 4 filed Sep 17, 2026, https://www.sec.gov/Archives/edgar/data/1478320/000182088526000023/0001820885-26-000023-index.htm
- Harlan S. Robins, Chief Scientific Officer. Source: Form 4 filed Jul 23, 2026, https://www.sec.gov/Archives/edgar/data/1478320/000178085126000017/0001780851-26-000017-index.htm
- Sharon Benzeno, Chief Commercial Ofc Imm Med. LinkedIn: https://linkedin.com/in/sharon-benzeno-phd-a374a03. Source: Form 4 filed Jun 30, 2026, https://www.sec.gov/Archives/edgar/data/1478320/000178085426000008/0001780854-26-000008-index.htm
- Michelle Griffin, a member of our Board of Directors. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm
- Harlan Robins, PhD, Named in proxy. Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/1478320/000119312526177409/adpt-20260423.htm
- Katey Owen, PhD, Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/1478320/000119312526177409/adpt-20260423.htm
- Peter Neupert, Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/1478320/000119312526177409/adpt-20260423.htm
- Robert Hershberg, PhD, MD, Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/1478320/000119312526177409/adpt-20260423.htm
- Sharon Benzeno, PhD, Named in proxy. Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/1478320/000119312526177409/adpt-20260423.htm

## Recent 8-K events

- Nov 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526447290/adpt-20261104.htm
- Jul 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526323753/adpt-20260724.htm
- Jun 22, 2026: Item 1.01, Entry into a material definitive agreement; Item 1.02, Termination of a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 3.02, Unregistered sales of equity securities; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526277516/d28937d8k.htm
- Jun 15, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526271117/d65233d8k.htm
- Jun 9, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526263844/adpt-20260605.htm
- May 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526206455/adpt-20260505.htm
- Feb 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526039409/adpt-20260205.htm
- Jan 12, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526009840/d29941d8k.htm
- Dec 30, 2025: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312525335921/d81101d8k.htm
- Nov 5, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312525266974/adpt-20251105.htm

## Insider trades (Form 4)

- Nov 6, 2026: Julie Rubinstein (President and COO) sold 35,643 shares, about $954,442. Source: https://www.sec.gov/Archives/edgar/data/1478320/000178066426000051/0001780664-26-000051-index.htm
- Nov 3, 2026: Julie Rubinstein (President and COO) sold 35,643 shares, about $928,891. Source: https://www.sec.gov/Archives/edgar/data/1478320/000178066426000049/0001780664-26-000049-index.htm
- Oct 29, 2026: Julie Rubinstein (President and COO) sold 35,643 shares, about $998,097. Source: https://www.sec.gov/Archives/edgar/data/1478320/000178066426000047/0001780664-26-000047-index.htm
- Oct 26, 2026: Julie Rubinstein (President and COO) sold 35,643 shares, about $897,457. Source: https://www.sec.gov/Archives/edgar/data/1478320/000178066426000045/0001780664-26-000045-index.htm
- Oct 21, 2026: Julie Rubinstein (President and COO) sold 35,643 shares, about $879,088. Source: https://www.sec.gov/Archives/edgar/data/1478320/000178066426000043/0001780664-26-000043-index.htm
- Oct 16, 2026: Julie Rubinstein (President and COO) sold 35,643 shares, about $897,356. Source: https://www.sec.gov/Archives/edgar/data/1478320/000178066426000041/0001780664-26-000041-index.htm
- Oct 13, 2026: Julie Rubinstein (President and COO) sold 35,643 shares, about $919,870. Source: https://www.sec.gov/Archives/edgar/data/1478320/000178066426000039/0001780664-26-000039-index.htm
- Oct 8, 2026: Julie Rubinstein (President and COO) sold 35,643 shares, about $948,223. Source: https://www.sec.gov/Archives/edgar/data/1478320/000178066426000037/0001780664-26-000037-index.htm
- Oct 6, 2026: Susan Bobulsky (Chief Commercial Officer, MRD) sold 6,444 shares, about $193,320. Source: https://www.sec.gov/Archives/edgar/data/1478320/000182088526000025/0001820885-26-000025-index.htm
- Oct 5, 2026: Julie Rubinstein (President and COO) sold 35,643 shares, about $1.0M. Source: https://www.sec.gov/Archives/edgar/data/1478320/000178066426000035/0001780664-26-000035-index.htm
- Oct 1, 2026: Francis Lo (Chief People Officer) sold 26,792 shares, about $757,697. Source: https://www.sec.gov/Archives/edgar/data/1478320/000178066026000024/0001780660-26-000024-index.htm
- Sep 16, 2026: Francis Lo (Chief People Officer) sold 115,406 shares, about $3.2M. Source: https://www.sec.gov/Archives/edgar/data/1478320/000178066026000022/0001780660-26-000022-index.htm
- Sep 15, 2026: Susan Bobulsky (Chief Commercial Officer, MRD) sold 1,195 shares, about $32,265. Source: https://www.sec.gov/Archives/edgar/data/1478320/000182088526000023/0001820885-26-000023-index.htm
- Aug 26, 2026: Katey Einterz Owen (Director) sold 9,615 shares, about $249,990. Source: https://www.sec.gov/Archives/edgar/data/1478320/000185257826000005/0001852578-26-000005-index.htm
- Aug 18, 2026: Robert Hershberg (Director) sold 30,664 shares, about $748,208. Source: https://www.sec.gov/Archives/edgar/data/1478320/000127413926000004/0001274139-26-000004-index.htm

## What management said

- "Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue" Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies (8-K filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526447290/adpt-ex99_1.htm

## Latest filings

- 8-K filed Jul 29, 2026: https://www.sec.gov/Archives/edgar/data/1478320/000119312526323753/adpt-20260724.htm
- 10-K filed Feb 26, 2026: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm
- 10-Q filed Aug 4, 2026: https://www.sec.gov/Archives/edgar/data/1478320/000119312526332940/adpt-20260630.htm
- DEF 14A filed Apr 24, 2026: https://www.sec.gov/Archives/edgar/data/1478320/000119312526177409/adpt-20260423.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/